|
|
Volumn 343, Issue 24, 2000, Pages 1799-1801
|
|
When and how to treat chronic lymphocytic leukemia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTILEUKEMIC AGENT;
CHLORAMBUCIL;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUDARABINE;
MONOCLONAL ANTIBODY;
PREDNISONE;
PURINE DERIVATIVE;
VINCRISTINE;
ACUTE DISEASE;
ALLOGENIC BONE MARROW TRANSPLANTATION;
AUTOLOGOUS BONE MARROW TRANSPLANTATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GENETICS;
CANCER REGRESSION;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
CELL DIFFERENTIATION;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL FEATURE;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DRUG CHOICE;
DRUG INDUCED DISEASE;
EDITORIAL;
HUMAN;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
PROGNOSIS;
TREATMENT INDICATION;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CHLORAMBUCIL;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
NEOPLASM STAGING;
PROGNOSIS;
REMISSION INDUCTION;
SURVIVAL RATE;
VIDARABINE;
|
|
EID: 0034649716
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM200012143432410 Document Type: Editorial |
|
Times cited : (112)
|
|
References (14)
|
